Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

385 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failure.
Suzuki H, Hirashima T, Okamoto N, Yamadori T, Tamiya M, Morishita N, Shiroyama T, Takeoka S, Osa A, Azuma Y, Kawase I. Suzuki H, et al. Among authors: hirashima t. Asia Pac J Clin Oncol. 2015 Jun;11(2):121-8. doi: 10.1111/ajco.12199. Epub 2014 May 9. Asia Pac J Clin Oncol. 2015. PMID: 24811212
Prognosis of small-cell lung cancer since the introduction of amrubicin.
Suzuki H, Hirashima T, Kobayashi M, Sasada S, Okamoto N, Tamiya M, Matsuura Y, Morishita N, Uehara N, Matsui K, Kawase I. Suzuki H, et al. Among authors: hirashima t. Med Oncol. 2011 Dec;28(4):1430-5. doi: 10.1007/s12032-010-9623-z. Epub 2010 Jul 15. Med Oncol. 2011. PMID: 20632217
Long-term amrubicin chemotherapy for small-cell lung cancer.
Higashiguchi M, Suzuki H, Hirashima T, Kobayashi M, Goya S, Okamoto N, Matsuura Y, Tamiya M, Morishita N, Kawase I. Higashiguchi M, et al. Among authors: hirashima t. Anticancer Res. 2012 Apr;32(4):1423-7. Anticancer Res. 2012. PMID: 22493380
Clinical significance of the serum crosslinked N-telopeptide of type I collagen as a prognostic marker for non-small-cell lung cancer.
Tamiya M, Kobayashi M, Morimura O, Yasue T, Nakasuji T, Satomu M, Kohei O, Takayuki S, Morishita N, Suzuki H, Sasada S, Okamoto N, Hirashima T, Kawase I. Tamiya M, et al. Among authors: hirashima t. Clin Lung Cancer. 2013 Jan;14(1):50-4. doi: 10.1016/j.cllc.2012.03.012. Epub 2012 May 18. Clin Lung Cancer. 2013. PMID: 22609050
Efficacy of carboplatin and paclitaxel with bevacizumab as salvage chemotherapy for non-small cell lung cancer after failure of platinum-doublet chemotherapy.
Tamiya M, Tamiya A, Nakao K, Asami K, Okishio K, Satomu M, Shiroyama T, Morishita N, Suzuki H, Sasada S, Okamoto N, Okishio K, Kawaguchi T, Kobayashi M, Atagi S, Hirashima T, Kawase I. Tamiya M, et al. Among authors: hirashima t. Anticancer Res. 2012 Aug;32(8):3553-7. Anticancer Res. 2012. PMID: 22843945
Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer.
Minami S, Kijima T, Shiroyama T, Okafuji K, Hirashima T, Uchida J, Imamura F, Osaki T, Nakatani T, Ogata Y, Yamamoto S, Namba Y, Otsuka T, Tachibana I, Komuta K, Kawase I. Minami S, et al. Among authors: hirashima t. BMC Res Notes. 2013 Jan 3;6:3. doi: 10.1186/1756-0500-6-3. BMC Res Notes. 2013. PMID: 23281805 Free PMC article. Clinical Trial.
385 results